| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Pathology and Laboratory Medicine (S.L.A.), Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5G 1X5 Canada; and Department of Physiology and Pharmacology (D.K.G.) and Vollum Institute (M.A.K., M.J.L.) Oregon Health Sciences University, Portland, Oregon 97210
Address all correspondence and requests for reprints to: Dr. Sylvia L. Asa, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: sasa{at}mtsinai.on.ca
Tuberoinfundibular dopamine tonically inhibits PRL expression and secretion from the pituitary gland by the activation of dopamine D2 receptors (D2R) localized on lactotrophs. Mutant female mice that lack D2Rs have persistent hyperprolactinemia but also develop extensive hyperplasia of pituitary lactotrophs and peliosis of the adenohypophysis at 9 to 12 months of age, while age-matched male D2R-deficient mice have no morphologic adenohypophysial lesion. We now report that both female and male D2R-deficient mice 17 to 20 months of age develop pituitary lactotroph adenomas. Of 12 aged female mice examined, all developed monohormonal PRL-immunoreactive neoplasms that had a characteristic juxtanuclear Golgi pattern of PRL staining and loss of the reticulin fiber network. Several of these adenomas were 50-fold larger than normal glands with marked suprasellar extension and invasion of brain but no gross evidence of distant metastases. They also had striking peliosis that was more marked than the lesion seen in the hyperplastic pituitaries of the younger females. These findings demonstrate that a chronic loss of neurohormonal dopamine inhibition promotes the hyperplasia-neoplasia sequence in adenohypophysial lactotrophs. Our results are analogous to previous data indicating that protracted stimulation of adenohypophysial cells by hormones or growth factors results in proliferation with initial hyperplasia followed by the development of neoplasia. Six aged male D2R-deficient mice had slightly enlarged anterior pituitaries similar in size to normal female glands. However, each case exhibited multifocal, microscopic lactotroph adenomas with strong nuclear immunoreactivity for estrogen receptors and Pit-1 transcription factor. The unexpected development of adenomas in males without preexisting or concomitant hyperplasia suggests that prolonged loss of dopamine inhibition may also cause neoplasia by distinct cellular mechanisms in male and female animals.
This article has been cited by other articles:
 |
|
 |
|
  R. I. Holt Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists J Psychopharmacol, March 1, 2008; 22(2_suppl): 28 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yin, L. Williams-Simons, A. F. Parlow, S. Asa, and L. S. Kirschner Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis Mol. Endocrinol., February 1, 2008; 22(2): 380 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cristina, G. Diaz-Torga, A. Gongora, M. C. Guida, M. I. Perez-Millan, A. Baldi, and D. Becu-Villalobos Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1341 - E1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bontempi, C. Fiorentini, C. Busi, N. Guerra, P. Spano, and C. Missale Identification and Characterization of Two Nuclear Factor-{kappa}B Sites in the Regulatory Region of the Dopamine D2 Receptor Endocrinology, May 1, 2007; 148(5): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Garcia-Tornadu, M. Rubinstein, B. D Gaylinn, D. Hill, E. Arany, M. J Low, G. Diaz-Torga, and D. Becu-Villalobos GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin. J. Endocrinol., September 1, 2006; 190(3): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Sarkar, K. Chaturvedi, S. Oomizu, N. I. Boyadjieva, and C. P. Chen Dopamine, Dopamine D2 Receptor Short Isoform, Transforming Growth Factor (TGF)-{beta}1, and TGF-{beta} Type II Receptor Interact to Inhibit the Growth of Pituitary Lactotropes Endocrinology, October 1, 2005; 146(10): 4179 - 4188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cristina, G. Diaz-Torga, A. Baldi, A. Gongora, M. Rubinstein, M. J. Low, and D. Becu-Villalobos Increased Pituitary Vascular Endothelial Growth Factor-A in Dopaminergic D2 Receptor Knockout Female Mice Endocrinology, July 1, 2005; 146(7): 2952 - 2962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Kippin, S. Kapur, and D. van der Kooy Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs J. Neurosci., June 15, 2005; 25(24): 5815 - 5823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Mohammad, D. D. Seachrist, C. C. Quirk, and J. H. Nilson Reexpression of p8 Contributes to Tumorigenic Properties of Pituitary Cells and Appears in a Subset of Prolactinomas in Transgenic Mice that Hypersecrete Luteinizing Hormone Mol. Endocrinol., October 1, 2004; 18(10): 2583 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Simpson, A. M. McNicol, D. C. Murray, A. Bahar, H. E. Turner, J. A. H. Wass, M. M. Esiri, R. N. Clayton, and W. E. Farrell Molecular Pathology Shows p16 Methylation in Nonadenomatous Pituitaries from Patients with Cushing's Disease Clin. Cancer Res., March 1, 2004; 10(5): 1780 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Mohammad, R. A. Abbud, A. F. Parlow, J. S. Lewin, and J. H. Nilson Targeted Overexpression of Luteinizing Hormone Causes Ovary-Dependent Functional Adenomas Restricted to Cells of the Pit-1 Lineage Endocrinology, October 1, 2003; 144(10): 4626 - 4636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paez-Pereda, D. Giacomini, D. Refojo, A. C. Nagashima, U. Hopfner, Y. Grubler, A. Chervin, V. Goldberg, R. Goya, S. T. Hentges, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk PNAS, February 4, 2003; 100(3): 1034 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Hentges and M. J. Low Ovarian Dependence for Pituitary Tumorigenesis in D2 Dopamine Receptor-Deficient Mice Endocrinology, December 1, 2002; 143(12): 4536 - 4543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Iaccarino, T. A. Samad, C. Mathis, H. Kercret, R. Picetti, and E. Borrelli Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs PNAS, October 29, 2002; 99(22): 14530 - 14535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Rulli, A. Kuorelahti, O. Karaer, L. J. Pelliniemi, M. Poutanen, and I. Huhtaniemi Reproductive Disturbances, Pituitary Lactotrope Adenomas, and Mammary Gland Tumors in Transgenic Female Mice Producing High Levels of Human Chorionic Gonadotropin Endocrinology, October 1, 2002; 143(10): 4084 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Banihashemi and P. R. Albert Dopamine-D2S Receptor Inhibition of Calcium Influx, Adenylyl Cyclase, and Mitogen-Activated Protein Kinase in Pituitary Cells: Distinct G{alpha} and G{beta}{gamma} Requirements Mol. Endocrinol., October 1, 2002; 16(10): 2393 - 2404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Liu, R. E. Baker, C. Sun, V. C. Sundmark, and H. P. Elsholtz Activation of Go-coupled Dopamine D2 Receptors Inhibits ERK1/ERK2 in Pituitary Cells. A KEY STEP IN THE TRANSCRIPTIONAL SUPPRESSION OF THE PROLACTIN GENE J. Biol. Chem., September 20, 2002; 277(39): 35819 - 35825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ozawa, M. Yamada, T. Satoh, T. Monden, K. Hashimoto, H. Kohga, Y. Hashiba, T. Sasaki, and M. Mori Transcriptional Regulation of the Human PRL-Releasing Peptide (PrRP) Receptor Gene by a Dopamine 2 Receptor Agonist: Cloning and Characterization of the Human PrRP Receptor Gene and Its Promoter Region Mol. Endocrinol., April 1, 2002; 16(4): 785 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Diaz-Torga, C. Feierstein, C. Libertun, D. Gelman, M. A. Kelly, M. J. Low, M. Rubinstein, and D. Becu-Villalobos Disruption of the D2 Dopamine Receptor Alters GH and IGF-I Secretion and Causes Dwarfism in Male Mice Endocrinology, April 1, 2002; 143(4): 1270 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Albert Editorial: Dopamine-D2-Mediated Inhibition of TRH-Induced PLC Activation in Pituitary Cells--Direct or Indirect? Endocrinology, March 1, 2002; 143(3): 744 - 746. [Full Text] [PDF]
|
|
|
|
|
|
C. Fiorentini, N. Guerra, M. Facchetti, A. Finardi, L. Tiberio, L. Schiaffonati, P. Spano, and C. Missale Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-{kappa}B Mol. Endocrinol., February 1, 2002; 16(2): 353 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Andersen and M. G. Rosenfeld POU Domain Factors in the Neuroendocrine System: Lessons from Developmental Biology Provide Insights into Human Disease Endocr. Rev., February 1, 2001; 22(1): 2 - 35. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
